Diffuse large B-cell lymphoma

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

Retrieved on: 
Wednesday, July 19, 2023
Rituximab, Diffuse large B-cell lymphoma, DLBCL, Data monitoring committee, Patient, ADC, Pomerantz, News, NYSE, DMC, Pharmaceutical industry

NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT).

Key Points: 
  • NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT).
  • The investigation concerns whether ADC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • On July 11, 2023, ADC “announced a voluntary pause in the enrollment of new patients in the Phase 2 LOTIS-9 clinical trial .
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

Retrieved on: 
Tuesday, July 11, 2023
COPD, Rituximab, Table, Diffuse large B-cell lymphoma, DLBCL, Data monitoring committee, Safety, European Medicines Agency, EMA, Chronic obstructive pulmonary disease, Fibrosis, COVID-19, Patient, ADC, FDA, Therapy, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pulmonary edema, NYSE, DMC, Food, Pharmaceutical industry

These respiratory-related treatment-emergent adverse events (TEAEs) included seven Grade 5 fatal events and five Grade 3 or Grade 4 respiratory-related TEAEs.

Key Points: 
  • These respiratory-related treatment-emergent adverse events (TEAEs) included seven Grade 5 fatal events and five Grade 3 or Grade 4 respiratory-related TEAEs.
  • Four out of the five Grade 3 or Grade 4 events have since resolved and the patients have completed treatment per protocol.
  • The Company’s decision to pause enrollment enables time to evaluate data around the TEAEs and determine next steps.
  • “Our top priority is the safety of every patient who participates in our clinical trials,” said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.

Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Retrieved on: 
Monday, July 3, 2023
CD19, Takeda, Osteoporosis, CD20, Neoplasm, Biogen, VEGF, Patient, Epitope, Epithelial cell adhesion molecule, Zymeworks, Therapy, Lonza, Bone marrow, Research, Genentech, Gilead, EMA, Boehringer Ingelheim, ABL, Growth, ADC, PD-1, FDA, III, NMPA, Hubert Mordek, Roche, Docetaxel, Bispecific monoclonal antibody, Gilead Sciences, CD3, IGM, HER2, Immunoglobulin M, Conjugation, Cancer, Macrogen, Dragonfly, NSCLC, Antibody, Immunotherapy, Acute myeloid leukemia, CD33, Syndrome, Immune system, Pembrolizumab, Economics, Caris, Jazz, PRV, CEA, Diffuse large B-cell lymphoma, NHL, LAS, MDS, AML, CD123, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, BCMA, Vaccine, Fine chemical, Pharmaceutical industry, WNT

LAS VEGAS, July 3, 2023 /PRNewswire/ -- DelveInsight's 'Bispecific Antibody Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline bispecific antibodies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the bispecific antibody competitive domain.

Key Points: 
  • The bispecific antibody pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
  • Over 250+ bispecific antibody companies are evaluating 300+ bispecific antibody drugs in various stages of development, and their anticipated acceptance in the bispecific antibody market would significantly increase market revenue.
  • Promising bispecific antibody pipeline drugs such as Amivantamab, Blinatumomab, Ivonescimab, Zanidatamab, Glofitamab, Imvotamab, MGD024, PRV 3279, KN-046, SI-B001, REGN-5458, BI-905711, and others are under different phases of bispecific antibody clinical trials.
  • The collaboration is intended to help in the development and manufacturing of ABL Bio's new bispecific antibody product.

Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Retrieved on: 
Monday, July 3, 2023
CD19, Takeda, Osteoporosis, CD20, Neoplasm, Biogen, VEGF, Patient, Epitope, Epithelial cell adhesion molecule, Zymeworks, Therapy, Lonza, Bone marrow, Research, Genentech, Gilead, EMA, Boehringer Ingelheim, ABL, Growth, ADC, PD-1, FDA, III, NMPA, Hubert Mordek, Roche, Docetaxel, Bispecific monoclonal antibody, Gilead Sciences, CD3, IGM, HER2, Immunoglobulin M, Conjugation, Cancer, Macrogen, Dragonfly, NSCLC, Antibody, Immunotherapy, Acute myeloid leukemia, CD33, Syndrome, Immune system, Pembrolizumab, Economics, Caris, Jazz, PRV, CEA, Diffuse large B-cell lymphoma, NHL, LAS, MDS, AML, CD123, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, BCMA, Vaccine, Fine chemical, Pharmaceutical industry, WNT

LAS VEGAS, July 3, 2023 /PRNewswire/ -- DelveInsight's 'Bispecific Antibody Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline bispecific antibodies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the bispecific antibody competitive domain.

Key Points: 
  • The bispecific antibody pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
  • Over 250+ bispecific antibody companies are evaluating 300+ bispecific antibody drugs in various stages of development, and their anticipated acceptance in the bispecific antibody market would significantly increase market revenue.
  • Promising bispecific antibody pipeline drugs such as Amivantamab, Blinatumomab, Ivonescimab, Zanidatamab, Glofitamab, Imvotamab, MGD024, PRV 3279, KN-046, SI-B001, REGN-5458, BI-905711, and others are under different phases of bispecific antibody clinical trials.
  • The collaboration is intended to help in the development and manufacturing of ABL Bio's new bispecific antibody product.

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL

Retrieved on: 
Friday, June 9, 2023
Online, Lymphoma, Neutropenia, Abstract, Wiley (publisher), Diffuse large B-cell lymphoma, DLBCL, European Hematology Association, Non-Hodgkin lymphoma, OH, Doctor of Philosophy, Gamma-glutamyltransferase, B-cell lymphoma, ORR, Medical College of Wisconsin, International Conference on Conceptual Modeling, CEST, Ira Middleswarth & Son, Inc., EHA, CR, Pivotal, ADC, Therapy, NYSE, Thrombocytopenia, Conference, Safety, Disease, Pharmaceutical industry, Book, MD, Patient, Gallery

LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Key Points: 
  • LAUSANNE, Switzerland, June 09, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
  • “We’re pleased to be sharing updated LOTIS-2 results demonstrating the long‐term efficacy and safety of ZYNLONTA with the lymphoma community at EHA2023 and 17-ICML,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.
  • The median (range) time to response was 41.0 (35 to 247) days for all responders and 42.0 (36 to 247) days for patients with a CR.
  • All-grade treatment‐emergent adverse events occurring in ≥30% of all patients were increased gamma-glutamyltransferase (42%), neutropenia (40%), and thrombocytopenia (33%).

Lung Cancer Therapies Market to Amplify Significantly over 2022-2029 - Brandessence Market Research

Retrieved on: 
Monday, May 29, 2023
Smoker, Atezolizumab, Complex conjugate, Lung cancer, Tobacco, Alectinib, Cough, Hospital, Acquisition, Patient, Investment, EGFR, Diffuse large B-cell lymphoma, Risk, Eli Lilly and Company, Spacecraft, Health, Air pollution, Virus, Disease, ALK, Therapy, Crizotinib, Entrectinib, Research, Paclitaxel, Boehringer Ingelheim, ARIAD Pharmaceuticals, Growth, Pembrolizumab, Smoking, Erlotinib, Docetaxel, Gas, Cancer, Osimertinib, Chest pain, Traction, Blood, Immune system, ROS1, Trastuzumab emtansine, Teva Pharmaceuticals, Radiation, Pfizer, Bristol Myers Squibb, AstraZeneca, Lung, Novartis, Smoke, Nivolumab, Pharmaceutical industry, Renewable energy, Vaccine, Bayer, Genentech, Talimogene laherparepvec

With rapid evolution in the field of medical research, numerous therapies aimed at treating lung cancer have been developed.

Key Points: 
  • With rapid evolution in the field of medical research, numerous therapies aimed at treating lung cancer have been developed.
  • The business intelligence report on Lung Cancer Therapies Market by Brandessence Market Research is curated with an aim to provide the industry participants with a succulent overview of this industry.
  • By treatment, the chemotherapy segment is projected to amass notable gains due to its efficacy in treating lung cancer.
  • The Lung Cancer Therapies Market is anticipated to garner significant returns over the estimated timeline of 2022-2029.

Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress

Retrieved on: 
Thursday, May 25, 2023
Biotechnology, General Health, Pharmaceutical, Health, Safety, Refractory, Science, Translational research, Update, Myeloproliferative neoplasm, Myelodysplastic syndrome, ALK, Center for International Blood and Marrow Transplant Research, Activin and inhibin, DLBCL, European Hematology Association, Research, Polycythemia vera, Combination therapy, S110, Chronic lymphocytic leukemia, Abstract, Combination, Chronic myelogenous leukemia, Cytokine release syndrome, ALL, CRS, Relapse, OPTIC, Lymphoma, MOST, Cancer, Diffuse large B-cell lymphoma, Neoplasm, ALK2, Abstract (summary), CML, PV, ASCO, BET, American Society of Clinical Oncology, EHA, Annual general meeting, Anemia, Society, Pharmaceutical industry, Communications satellite, Allotransplantation, Hydroxycarbamide, Primary myelofibrosis, Patient

ET)

Key Points: 
  • ET)
    Phase 1b, Open-Label Study of Add-On Therapy with CK0804 in Participants with Myelofibrosis, with Suboptimal Response to Ruxolitinib (Abstract #TPS7087.
  • ET)1
    A Phase 1/2 Study of Retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) Combination Therapy in Patients (Pts) with Advanced Solid Tumors (Abstract #2599.
  • ET)
    Abstracts are available on the EHA2023 Congress platform and accessible for on-demand viewing until August 15, 2023.
  • ET)5
    For full session details and data presentation listings, please see the ASCO ( https://conferences.asco.org ) and EHA2023 ( https://ehaweb.org/congress ) online programs.

ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress

Retrieved on: 
Thursday, May 11, 2023
Health, Science, Research, Clinical Trials, Oncology, Diffuse large B-cell lymphoma, DLBCL, European Hematology Association, OH, Doctor of Philosophy, B-cell lymphoma, Hematology, Pivotal, ADC, Therapy, NYSE, Pharmaceutical industry, MD, Patient

ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), have been accepted for presentation at the European Hematology Association 2023 Hybrid Congress (EHA2023), which will be held in Frankfurt, Germany from June 8-11, 2023.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) today announced updated results from LOTIS-2, the pivotal Phase 2 clinical trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), have been accepted for presentation at the European Hematology Association 2023 Hybrid Congress (EHA2023), which will be held in Frankfurt, Germany from June 8-11, 2023.
  • “We are encouraged by the latest developments from our pivotal LOTIS-2 trial, which further validate the long‐term disease control of ZYNLONTA in heavily pretreated patients with DLBCL,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.
  • “ZYNLONTA has substantial single-agent antitumor activity and produces durable responses with an acceptable safety profile.
  • We look forward to sharing our new data with the hematology community at EHA2023.”
    Details of ADC Therapeutics’ poster presentation are as follows:
    Long-Term Responses with Loncastuximab Tesirine: Updated Results From LOTIS-2, the Pivotal Phase 2 Study In Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Presenting Author: Paolo F. Caimi, MD, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA

Cryoport Reports Fourth Quarter and Full Year 2022 Results

Retrieved on: 
Thursday, February 23, 2023
Genomics, Cell, Acquisition, Security (finance), European Commission, DSM-IV codes, COVID-19, EBITDA, Civil service commission, Medicine, Patient, Livestock, Animal Health, Form, Collection, Partnership, GAAP, Investment, Blas, Cryopreservation, Diffuse large B-cell lymphoma, Growth, Regenerative medicine, Environment, CO, Form 10-K, Risk, SEC filing, Annual report, Reproductive medicine, Element, EMA, DLBCL, Temperature, Syneos Health, Bristol Myers Squibb, Pharmaceutical industry, Vaccine, Video game, Fine chemical, Cryptocurrency, Renewable energy, Mobile phone

Fourth quarter 2022 performance by market was as follows:

Key Points: 
  • Fourth quarter 2022 performance by market was as follows:
    Biopharma/Pharma revenue increased to $50.6 million, up 9% or $4.2 million for the fourth quarter of 2022, compared to $46.3 million for the fourth quarter of 2021.
  • Animal Health revenue was $7.5 million, down 3% or $0.2 million for the fourth quarter of 2022, compared to $7.7 million for the fourth quarter of 2021.
  • Reproductive Medicine revenue was $2.3 million for the fourth quarter of 2022, compared to $2.4 million for the fourth quarter of 2021.
  • Gross margin was 43.5% for the fourth quarter of 2022, compared to 41.0% in the fourth quarter of 2021.

Eurofins Viracor Launches Ground-Breaking Test for Assessing Expansion and Persistence of CAR-T Therapy in Cancer Patients

Retrieved on: 
Thursday, February 16, 2023
Science, Research, Medical Supplies, Oncology, Health, COVID-19, Infectious Diseases, Other Health, Infection, Cancer, Allergy, Diffuse large B-cell lymphoma, Patient, Immunotherapy, Vaccine, Pharmaceutical industry, Eurofins Scientific

The test, based on a method developed by Eurofins Viracor, is designed to help clinicians better understand how CAR-T therapy is performing for their patients.

Key Points: 
  • The test, based on a method developed by Eurofins Viracor, is designed to help clinicians better understand how CAR-T therapy is performing for their patients.
  • CAR-T therapy is a revolutionary form of immunotherapy that uses genetically engineered T-cells to attack cancer cells and has shown promising results in treating a variety of cancers.
  • Research has demonstrated that the persistence and expansion of CAR-T therapy are important indicators of how long the therapy is likely to remain effective in the patient.
  • The launch of this test marks an important step forward in the evaluation and management of CAR-T therapy in cancer patients.